HUE059768T2 - 5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények - Google Patents

5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények

Info

Publication number
HUE059768T2
HUE059768T2 HUE17837516A HUE17837516A HUE059768T2 HU E059768 T2 HUE059768 T2 HU E059768T2 HU E17837516 A HUE17837516 A HU E17837516A HU E17837516 A HUE17837516 A HU E17837516A HU E059768 T2 HUE059768 T2 HU E059768T2
Authority
HU
Hungary
Prior art keywords
cholesthene
25hc3s
diol
sulfate
pharmaceutically acceptable
Prior art date
Application number
HUE17837516A
Other languages
English (en)
Hungarian (hu)
Inventor
Shunlin Ren
Leyuan Xu
Yanxia Ning
Jin Kim
Weiqi Lin
Meej Kim
Andrew Miksztal
Hongwei Wu
Min Lee
Wilma Tamraz
Original Assignee
Univ Virginia Commonwealth
The Us Gov As Represented By
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth, The Us Gov As Represented By, Durect Corp filed Critical Univ Virginia Commonwealth
Publication of HUE059768T2 publication Critical patent/HUE059768T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HUE17837516A 2016-08-02 2017-08-01 5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények HUE059768T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662370024P 2016-08-02 2016-08-02
US201762470578P 2017-03-13 2017-03-13

Publications (1)

Publication Number Publication Date
HUE059768T2 true HUE059768T2 (hu) 2022-12-28

Family

ID=61073854

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17837516A HUE059768T2 (hu) 2016-08-02 2017-08-01 5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények

Country Status (22)

Country Link
US (4) US20190269695A1 (cg-RX-API-DMAC7.html)
EP (2) EP4101861A1 (cg-RX-API-DMAC7.html)
JP (3) JP2019524772A (cg-RX-API-DMAC7.html)
KR (3) KR102593667B1 (cg-RX-API-DMAC7.html)
CN (2) CN109983025B (cg-RX-API-DMAC7.html)
AU (2) AU2017305239C1 (cg-RX-API-DMAC7.html)
CA (1) CA3031224A1 (cg-RX-API-DMAC7.html)
DK (1) DK3494125T3 (cg-RX-API-DMAC7.html)
EA (1) EA201990438A1 (cg-RX-API-DMAC7.html)
ES (1) ES2922933T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220932T1 (cg-RX-API-DMAC7.html)
HU (1) HUE059768T2 (cg-RX-API-DMAC7.html)
IL (2) IL298681A (cg-RX-API-DMAC7.html)
LT (1) LT3494125T (cg-RX-API-DMAC7.html)
MX (2) MX2019001323A (cg-RX-API-DMAC7.html)
PL (1) PL3494125T3 (cg-RX-API-DMAC7.html)
PT (1) PT3494125T (cg-RX-API-DMAC7.html)
RS (1) RS63529B1 (cg-RX-API-DMAC7.html)
SI (1) SI3494125T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200330T1 (cg-RX-API-DMAC7.html)
TW (2) TW202426000A (cg-RX-API-DMAC7.html)
WO (1) WO2018026781A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
IL294448A (en) 2013-12-24 2022-09-01 Univ Virginia Commonwealth Uses of oxidized cholesterol sulfates
KR102593667B1 (ko) 2016-08-02 2023-10-24 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
EP4037650A4 (en) * 2019-09-30 2023-10-18 Durect Corporation TREATMENT OF ALCOHOLIC HEPATITIS
AU2021221109A1 (en) * 2020-02-11 2022-08-25 Durect Corporation Treatment of infectious diseases
WO2021202608A1 (en) * 2020-03-31 2021-10-07 The Regents Of The University Of Michigan Serum metabolites as biomarkers for carnitine treatment of sepsis
EP4153164A4 (en) * 2020-05-22 2024-06-26 Durect Corporation Treatment of non-alcoholic steatohepatitis (nash)
JP2023531735A (ja) * 2020-06-26 2023-07-25 デュレクト コーポレーション インスリン抵抗性、糖尿病、及び前糖尿病の少なくとも１つを処置するための酸素化コレステロールスルフェート類の使用
CN112967234B (zh) * 2021-02-09 2022-12-09 复旦大学附属中山医院 冠状动脉功能生理学病变模式定量评价方法
US20240425545A1 (en) * 2021-06-25 2024-12-26 Durect Corporation 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same
CN113750039B (zh) * 2021-10-26 2023-08-18 浙江中医药大学 一种黄芩苷-海藻酸钙温敏纳米凝胶、制备方法及其应用
WO2023196412A1 (en) * 2022-04-06 2023-10-12 Nobias Therapeutics, Inc. Liquid formulations comprising mitogen-activated protein kinase kinase (mek) inhibitors and methods using same
CN119896674A (zh) * 2023-10-27 2025-04-29 上海交通大学医学院附属新华医院 胆固醇硫酸酯在制备治疗特应性皮炎的药物中的应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
BE794362A (fr) 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3928397A (en) 1973-03-02 1975-12-23 Eisai Co Ltd New 5-cholestene derivatives and preparation thereof
US3822254A (en) 1973-05-21 1974-07-02 Hoffmann La Roche Synthesis of 25-hydroxycholesterol
US4264512A (en) 1975-09-29 1981-04-28 The Regents Of The University Of California 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof
US4202891A (en) 1977-05-16 1980-05-13 Kandutsch Andrew A 15-Oxygenated sterol compounds and the use of such compounds to inhibit the biosynthesis of sterols
GB1595020A (en) 1977-06-24 1981-08-05 Chugai Pharmaceutical Co Ltd 3a-hydroxy steroid derivatives of the cholestane series
US4427668A (en) 1982-04-01 1984-01-24 New York University 26-Hydroxycholesterol and derivatives and analogs thereof in regulation of cholesterol accumulation in body tissue
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5510340A (en) 1992-06-12 1996-04-23 Sri International Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
US5371077A (en) 1992-08-03 1994-12-06 William Marsh Rice University Side chain derivatized 15-oxygenated sterols, methods of using them and a process for preparing them
US5599659A (en) 1993-03-11 1997-02-04 Breonics, Inc. Preservation solution for ex vivo, warm preservation of tissues, explants,organs and vascular endothelial cells comprising retinal-derived fibroblast growth factor, cyclodextrin and chondroitin sulfate
US5587368A (en) * 1993-11-30 1996-12-24 New York University Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury
WO1997000884A1 (en) 1995-06-23 1997-01-09 Novo Nordisk A/S Meiosis regulating compounds
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
BR9910415A (pt) 1998-05-13 2001-01-09 Novo Nordisk As Novos compostos, uso de compostos, e, processo de regular a meiose
KR20010043558A (ko) 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060025393A1 (en) 1999-04-30 2006-02-02 Shutsung Liao Steroid derivatives
BR0010197A (pt) 1999-04-30 2002-07-16 Arch Dev Corp Derivados de esteróides
EP1239848A2 (en) 1999-09-01 2002-09-18 University of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
JP4018312B2 (ja) 2000-02-21 2007-12-05 株式会社ルネサステクノロジ 無線通信装置
IN191090B (cg-RX-API-DMAC7.html) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
WO2002062302A2 (en) 2001-02-08 2002-08-15 The University Of Chicago Steroidal derivatives
US20020164310A1 (en) 2001-03-02 2002-11-07 Mgvs Ltd. Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
CN100360550C (zh) 2001-05-03 2008-01-09 芝加哥大学 肝脏x受体激动剂
WO2003039480A2 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
HRP20050149B1 (hr) * 2002-08-20 2014-09-12 Otsuka Pharmaceutical Co., Ltd. Formulacija aripiprazol kompleksa i postupak
CN1980899B (zh) 2004-06-30 2013-07-24 詹森药业有限公司 作为parp抑制剂的喹唑啉酮衍生物
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
EP1983972A4 (en) 2006-02-13 2012-01-25 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
DE102006021181B3 (de) 2006-05-06 2007-05-03 Laux, Thomas, Dr. Zahnprothesen-Trägerimplantat
GB0625965D0 (en) 2006-12-23 2007-02-07 Renovo Ltd Medicaments for wound healing
WO2009002873A1 (en) 2007-06-22 2008-12-31 Cvi Pharmaceuticals Limited Compounds, compositions and methods for reducing lipid levels
US8831674B2 (en) 2007-09-27 2014-09-09 Multi-Tech Systems, Inc. Message server
US20100291533A1 (en) 2008-01-04 2010-11-18 Soon Ha Kim Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect
WO2011077245A2 (en) 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
EP2608781A4 (en) * 2010-08-04 2014-01-29 Tixupharma INCLUSION COMPLEXES OF CYCLODEXTRINS WITH SPERMIDINE AND PROLIFERATIVE BZW. REPAIR COMPOSITIONS THEREWITH
KR101739816B1 (ko) * 2010-12-01 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
SMT202300232T1 (it) 2011-09-08 2023-09-06 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e relativi usi
HUE035073T2 (en) 2012-04-12 2018-05-02 Univ Virginia Commonwealth Novel cholesterol metabolite, 5-cholesten-3-beta-25-diol disulfate (25HCDS) for the treatment of metabolic diseases, hyperlipidemia, diabetes, fatty liver disease and atherosclerosis
EP2874709B1 (en) 2012-07-17 2018-12-19 The Regents Of The University Of Michigan Inhibitors of alpha-crystallin aggregation for the treatment for cataract
WO2014022841A1 (en) 2012-08-03 2014-02-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Cyclodextrin for the treatment of lysosomal storage diseases
US20140220112A1 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
EP2842547A1 (en) * 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Improved fenofibrate compositions
IL294448A (en) 2013-12-24 2022-09-01 Univ Virginia Commonwealth Uses of oxidized cholesterol sulfates
CN112121171A (zh) * 2014-10-07 2020-12-25 萨奇治疗股份有限公司 神经活性化合物及其使用方法
EA034524B1 (ru) 2014-10-10 2020-02-17 Вирджиния Коммонвелт Юниверсити Сульфаты окисленного холестерина для лечения пониженной лептиновой активности
CA2993196A1 (en) 2015-07-27 2017-02-02 Catacore, Inc Compositions for the treatment of cataracts
KR102593667B1 (ko) 2016-08-02 2023-10-24 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
US20190374554A1 (en) 2016-08-02 2019-12-12 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions
EP3493810A4 (en) 2016-08-02 2020-04-08 Durect Corporation COMPOSITIONS COMPRISING OXYGENATED CHOLESTEROL SULFATE AND AT LEAST POLYALKYLENE GLYCOL, CARBOXYMETHYLCELLULOSE OR POLYOXYLGLYCERIDE
EP4037650A4 (en) 2019-09-30 2023-10-18 Durect Corporation TREATMENT OF ALCOHOLIC HEPATITIS
IL294286A (en) 2019-12-27 2022-08-01 Durect Corp Crystalline and liquid crystalline sodium 25-hydroxycholine-5-yne-5-sulfate and methods for its preparation
AU2021221109A1 (en) 2020-02-11 2022-08-25 Durect Corporation Treatment of infectious diseases
TW202210082A (zh) 2020-05-22 2022-03-16 美商杜瑞克公司 非酒精性脂肪肝炎（ｎａｓｈ）之治療
EP4153164A4 (en) 2020-05-22 2024-06-26 Durect Corporation Treatment of non-alcoholic steatohepatitis (nash)
JP2023531735A (ja) 2020-06-26 2023-07-25 デュレクト コーポレーション インスリン抵抗性、糖尿病、及び前糖尿病の少なくとも１つを処置するための酸素化コレステロールスルフェート類の使用

Also Published As

Publication number Publication date
ES2922933T3 (es) 2022-09-21
TW201818945A (zh) 2018-06-01
JP2024105442A (ja) 2024-08-06
US11406646B2 (en) 2022-08-09
KR20190035776A (ko) 2019-04-03
MX2022013429A (es) 2022-11-14
IL264390B (en) 2022-12-01
SMT202200330T1 (it) 2022-11-18
CN109983025A (zh) 2019-07-05
JP2019524772A (ja) 2019-09-05
CN116747233A (zh) 2023-09-15
PT3494125T (pt) 2022-07-07
AU2017305239A1 (en) 2019-02-21
US20190269695A1 (en) 2019-09-05
KR20230152787A (ko) 2023-11-03
US12226423B2 (en) 2025-02-18
EA201990438A1 (ru) 2019-08-30
US20210169898A1 (en) 2021-06-10
LT3494125T (lt) 2022-11-10
AU2022204217A1 (en) 2022-07-07
PL3494125T3 (pl) 2022-10-17
AU2017305239B2 (en) 2022-03-17
IL264390A (en) 2019-02-28
CN109983025B (zh) 2023-04-04
KR102593667B1 (ko) 2023-10-24
HRP20220932T1 (hr) 2022-10-28
MX2019001323A (es) 2019-07-04
EP3494125B1 (en) 2022-06-22
TW202426000A (zh) 2024-07-01
SI3494125T1 (sl) 2022-10-28
AU2022204217B2 (en) 2024-04-04
US20250249021A1 (en) 2025-08-07
IL298681A (en) 2023-01-01
CA3031224A1 (en) 2018-02-08
IL264390B2 (en) 2023-04-01
EP3494125A1 (en) 2019-06-12
JP2022169550A (ja) 2022-11-09
RS63529B1 (sr) 2022-09-30
WO2018026781A1 (en) 2018-02-08
KR102465046B1 (ko) 2022-11-10
DK3494125T3 (da) 2022-08-01
AU2017305239C1 (en) 2022-08-18
TWI815796B (zh) 2023-09-21
KR20220154250A (ko) 2022-11-21
JP7487264B2 (ja) 2024-05-20
EP4101861A1 (en) 2022-12-14
EP3494125A4 (en) 2020-04-01
US20230047788A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
HUE059768T2 (hu) 5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények
HUE055838T2 (hu) Amfifil poliszacharid-származékok és azokat tartalmazó készítmények
IL269391A (en) Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
IL272089A (en) Compounds, compositions and methods
HUE048807T2 (hu) Egy sejtpenetráló peptidet, egy kargót és egy TLR peptidagonistát tartalmazó új komplex kolorektális rák kezelésére
HUE051877T2 (hu) Biciklusos származékok, eljárás elõállításukra és ezeket tartalmazó gyógyszerészeti készítmények
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
HUE050028T2 (hu) Neuroaktív szteroidok, készítmények és alkalmazásuk
HUE055658T2 (hu) PTHRP analógokat tartalmazó készítmények, ezeket tartalmazó transzdermális tapaszok és ezek alkalmazása
HUE054754T2 (hu) Eszközök és eljárások gyógyszerbeadásra és -keverésre, valamint ezekhez megfelelõ technikák betanítására
EP3491026A4 (en) HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
HUE063487T2 (hu) IAP antagonistával és egy anti-PD-1 molekulával történõ kombinációs rákellenes terápia
IL253793B (en) Abiraterone acetate complexes, a process for their preparation and pharmaceutical preparations containing them
LT3310345T (lt) Burnoje disperguojama tabletė, turinti estetrolio
BR112017020495A2 (pt) derivados de oxima carbamoilados e tiocarbamoilados ativos em termos pesticidas.
DK3294449T3 (da) Pulverformigt titaniumoxid, fremgangsmåde til fremstilling deraf og anvendelse deraf
HUE037383T2 (hu) Egy esztetrol komponenst tartalmazó, szájban diszpergálódó dózisegység
HUE046314T2 (hu) Pirazolopirimidon vagy pirrolotriazon származékok, eljárás ezek elõállítására és gyógyászati alkalmazásaik
HUE040022T2 (hu) Eljárás (S,S)-szekoizolaricirezinol diglükozid és (R,R)-szekoizolaricirezinol diglükozid elõállítására
HUE039808T2 (hu) [Bisz(trihidrokarbilszilil)aminoszilil]-funkcionalizált sztirol és eljárás ennek elõállítására
EP3381925A4 (en) Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof
IL248785B (en) Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents
EP3263061A4 (en) Overtube and medical manipulator system
HUE057871T2 (hu) Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók
EP3305804A4 (en) Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide